Soleil Boughton, Chief Legal Officer of Hims & Hers Health Inc (HIMS, Financial), sold 15,450 shares of the company on December 20, 2023, according to a recent SEC Filing. The transaction was executed at an average price of $8.71 per share, resulting in a total value of $134,615.50.
Hims & Hers Health Inc is a telehealth company that provides a modern approach to health and wellness. The company's platform connects consumers with licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to primary care, mental health, sexual health, dermatology, and more. Hims & Hers aims to make healthcare more accessible and convenient through its telemedicine services and personalized treatment plans.
Over the past year, the insider has sold a total of 287,440 shares and has not made any purchases of the company's stock. The recent sale by the insider is part of a trend observed over the past year, where there have been no insider buys and 57 insider sells for Hims & Hers Health Inc.
On the day of the insider's recent sale, shares of Hims & Hers Health Inc were trading at $8.71, giving the company a market capitalization of $1.823 billion.
The stock's price-to-GF-Value ratio stands at 0.74, with a GuruFocus Value of $11.72, indicating that Hims & Hers Health Inc is considered modestly undervalued based on its GF Value. The GF Value is calculated considering historical trading multiples, a GuruFocus adjustment factor based on the company's historical returns and growth, and future business performance estimates from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
